[
  {
    "drugId": "midazolam",
    "drugName": "Midazolam",
    "routes": [
      {
        "route": "subcutaneous",
        "toMidazolamFactor": 1.0,
        "doseUnit": "mg",
        "notes": null
      }
    ],
    "warningLevel": "none",
    "notes": null,
    "halfLife": "1–2 hours",
    "tMax": "30–60 minutes (SC)",
    "bioavailability": "~40% oral (SC only in palliative care)",
    "dosingGuidance": "Dosing not recommended greater than 3-hourly. Subcutaneous route only in palliative care due to low oral bioavailability (~40%)."
  },
  {
    "drugId": "clonazepam",
    "drugName": "Clonazepam",
    "routes": [
      {
        "route": "oral",
        "toMidazolamFactor": 4.0,
        "doseUnit": "mg",
        "notes": null
      },
      {
        "route": "subcutaneous",
        "toMidazolamFactor": 4.0,
        "doseUnit": "mg",
        "notes": null
      }
    ],
    "warningLevel": "none",
    "notes": null,
    "halfLife": "18–50 hours",
    "tMax": "1–4 hours",
    "bioavailability": ">80%",
    "dosingGuidance": "Outside the terminal phase, usually BD–TDS dosing. Can be given QID regular or Q4H PRN."
  },
  {
    "drugId": "lorazepam",
    "drugName": "Lorazepam",
    "routes": [
      {
        "route": "oral",
        "toMidazolamFactor": 2.0,
        "doseUnit": "mg",
        "notes": null
      }
    ],
    "warningLevel": "none",
    "notes": null,
    "halfLife": "10–20 hours",
    "tMax": "1–2 hours",
    "bioavailability": ">90%",
    "dosingGuidance": "Oral administration. High oral bioavailability makes PO:SC ratio approximately 1:1."
  },
  {
    "drugId": "diazepam",
    "drugName": "Diazepam",
    "routes": [
      {
        "route": "oral",
        "toMidazolamFactor": 0.25,
        "doseUnit": "mg",
        "notes": null
      }
    ],
    "warningLevel": "none",
    "notes": null,
    "halfLife": "20–100 hours (active metabolite desmethyldiazepam)",
    "tMax": "0.5–2 hours",
    "bioavailability": ">90%",
    "dosingGuidance": "Oral administration. Very long half-life due to active metabolites — accumulation risk in frail patients."
  },
  {
    "drugId": "phenobarbital",
    "drugName": "Phenobarbital",
    "routes": [
      {
        "route": "oral",
        "toMidazolamFactor": 0.125,
        "doseUnit": "mg",
        "notes": null
      },
      {
        "route": "subcutaneous",
        "toMidazolamFactor": 0.125,
        "doseUnit": "mg",
        "notes": null
      }
    ],
    "warningLevel": "specialist",
    "notes": "Specialist drug. At appropriate doses, phenobarbital supersaturates the GABA receptor cluster — escalating other benzodiazepines becomes futile. Reserved for status epilepticus and refractory terminal sedation.",
    "halfLife": "53–118 hours",
    "tMax": "1–6 hours",
    "bioavailability": "~95%",
    "dosingGuidance": "Specialist use only. Reserved for status epilepticus and refractory terminal sedation. If used at appropriate dosing, supersaturates the GABA cluster and escalating other BZDs is futile."
  }
]
